This analysis examines the current position and future outlook for J&J in the ethical pharmaceutical sector. The profile encompasses global and US company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

• Understand how J&J's mature product portfolio and risk of generic competition will impact sales growth over the forecast period
• Learn why J&J must continue to focus on M&A and licensing to generate sales growth over the forecast period
• Benchmark J&J's performance against key rivals in the ethical pharmaceutical sector